Literature DB >> 11064456

Differential activity of conditional MYC and its variant MYC-S in human mortal fibroblasts.

S K Hirst1, C Grandori.   

Abstract

We have explored the effects of the conditional MYC-estrogen receptor fusion protein, MYC-ERTM, in human mortal fibroblasts, WI38, on cell-cycle entry, apoptosis and gene expression. The results indicate that activation of MYC-ERTM in WI38 cells is sufficient to cause S phase entry of quiescent cells, which is preceded by phosphorylation of Rb and activation of the Cdk2-associated kinase. We also analysed the MYC protein variant, MYC-S, which lacks part of the transcriptional activation domain but includes the conserved MYC box II and 26 amino acids N-terminal to it. MYC-S was previously shown to promote proliferation and apoptosis of immortalized rodent cell lines. The results indicate that MYC-S has undetectable activity as an inducer of S phase or apoptosis of quiescent WI38 cells. However, Myc-S stimulates proliferation of WI38 cells in the presence of 10% fetal calf serum. Surprisingly, we found that MYC-S, previously considered solely a repressor of specific reporter genes, is instead a weak transactivator of endogenous target genes both in mortal and immortalized cells. In addition, MYC-S exhibit a weak repressor activity upon an endogenous target gene only in immortalized cells. MYC-S transcriptional properties suggest that MYC box II and the adjacent N-terminal amino acids, while not sufficient for full repression function, participate in transactivation of endogenous target genes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11064456     DOI: 10.1038/sj.onc.1203904

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter.

Authors:  C Bouchard; O Dittrich; A Kiermaier; K Dohmann; A Menkel; M Eilers; B Lüscher
Journal:  Genes Dev       Date:  2001-08-15       Impact factor: 11.361

Review 2.  MYC cofactors: molecular switches controlling diverse biological outcomes.

Authors:  Stephen R Hann
Journal:  Cold Spring Harb Perspect Med       Date:  2014-06-17       Impact factor: 6.915

Review 3.  Myc in model organisms: a view from the flyroom.

Authors:  Claire de la Cova; Laura A Johnston
Journal:  Semin Cancer Biol       Date:  2006-07-14       Impact factor: 15.707

4.  c-Myc transformation domain recruits the human STAGA complex and requires TRRAP and GCN5 acetylase activity for transcription activation.

Authors:  Xiaohui Liu; Jerusalem Tesfai; Yvonne A Evrard; Sharon Y R Dent; Ernest Martinez
Journal:  J Biol Chem       Date:  2003-03-26       Impact factor: 5.157

5.  Overexpression of c-Myc alters G(1)/S arrest following ionizing radiation.

Authors:  Joon-Ho Sheen; Robert B Dickson
Journal:  Mol Cell Biol       Date:  2002-03       Impact factor: 4.272

6.  Human c-Myc isoforms differentially regulate cell growth and apoptosis in Drosophila melanogaster.

Authors:  C Benassayag; L Montero; N Colombié; P Gallant; D Cribbs; D Morello
Journal:  Mol Cell Biol       Date:  2005-11       Impact factor: 4.272

7.  c-MYC apoptotic function is mediated by NRF-1 target genes.

Authors:  Fionnuala Morrish; Christopher Giedt; David Hockenbery
Journal:  Genes Dev       Date:  2003-01-15       Impact factor: 11.361

8.  Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study.

Authors:  Kathleen M Darcy; William E Brady; Jan K Blancato; Robert B Dickson; William J Hoskins; William P McGuire; Michael J Birrer
Journal:  Gynecol Oncol       Date:  2009-06-12       Impact factor: 5.482

9.  MB0 and MBI Are Independent and Distinct Transactivation Domains in MYC that Are Essential for Transformation.

Authors:  Qin Zhang; Kimberly West-Osterfield; Erick Spears; Zhaoliang Li; Alexander Panaccione; Stephen R Hann
Journal:  Genes (Basel)       Date:  2017-05-06       Impact factor: 4.096

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.